Every AXLRx MASH report, across 5 report types. Each is scoped to your asset and verified to a live source.
Rezdiffra and Wegovy now split the noncirrhotic MASH label. This is a Year 0 to Year 1 access and retention fight, not a pre-launch window.
The MASLD-to-MASH-to-F2-F3 funnel, NASH-CRN fibrosis staging, and the FIB-4-to-elastography diagnostic gap behind the 6.7M label-eligible pool.
Why Rezdiffra's $47,400 WAC lands inside ICER's value range, why the IRA reset hits semaglutide first, and how Part D routing shapes MASH access.
6.7 million Americans have F2-F3 MASH, but Rezdiffra has already reported 42,250+ patients on therapy and $311.3M in Q1 2026 revenue. This model triangulates population against real uptake, not a modeled guess.
Rezdiffra and Wegovy already hold the noncirrhotic F2-F3 label. The clearer opening for a new entrant is the compensated-cirrhosis boundary neither drug covers.
AXLRx publishes Competitive Intelligence, Disease Landscape, Payer & HTA, Market Sizing Model, and Launch Readiness for Metabolic Dysfunction-Associated Steatohepatitis. Each report is scoped to your asset, verified to a live source, and delivered in 72 hours.
Current MASH coverage spans United States. Additional markets can be commissioned against the same evidence standard.
Every figure is cited to a live source at the point of writing and re-checked in an independent audit pass. The latest MASH reports were updated July 2026.